Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis by Taleb, Soraya et al.
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 206 No. 10  2067-2077
www.jem.org/cgi/doi/10.1084/jem.20090545
2067
BRIEF DEFINITIVE REPORT
The immunoinflammatory response plays a 
prominent role in driving atherosclerotic lesion 
development, progression, and complications 
(Binder et al., 2002; Hansson and Libby, 2006; 
Tedgui and Mallat, 2006; Weber et al., 2008). 
Defining the direct roles of specific immune 
regulatory pathways in the modulation of ath­
erosclerosis is certainly of considerable interest 
(Tedgui and Mallat, 2006).
Suppressor of cytokine signaling (SOCS) pro­
teins are key physiological regulators of both 
innate and adaptive immunity, and control the 
development of various immunoinflammatory 
diseases (Yoshimura et al., 2007). SOCS3 is ex­
pressed in atherosclerotic lesions, and the cur­
rent paradigm suggests an atheroprotective role 
through inhibition of STAT3 signaling and the 
suppression of proinflammatory responses (Tang 
et al., 2005; Gharavi et al., 2007; Ortiz­Muñoz 
et al., 2009). However, its direct role in the 
control of the immune response of atheroscle­
rosis is still largely unknown.
Recent studies have addressed the role of 
T cell–specific SOCS3 expression on T cell 
differentiation and cytokine production. In­
triguingly, one study reported preferential Th3­ 
and/or Tr1­like differentiation and reduced 
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Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mor­
tality worldwide. Recent studies have clearly highlighted the critical role of the immuno­
inflammatory balance in the modulation of disease development and progression. However, 
the immunoregulatory pathways that control atherosclerosis remain largely unknown. We 
show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both inter­
leukin (IL)­17 and IL­10 production, induces an antiinflammatory macrophage phenotype, 
and leads to unexpected IL­17–dependent reduction in lesion development and vascular 
inflammation. In vivo administration of IL­17 reduces endothelial vascular cell adhesion 
molecule–1 expression and vascular T cell infiltration, and significantly limits atheroscle­
rotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL­17 and 
accelerates atherosclerosis. We also show that in human lesions, increased levels of signal 
transducer and activator of transcription (STAT) 3 phosphorylation and IL­17 are associ­
ated with a stable plaque phenotype. These results identify novel SOCS3­controlled IL­17 
regulatory pathways in atherosclerosis and may have important implications for the under­
standing of the increased susceptibility to vascular inflammation in patients with domi­
nant­negative STAT3 mutations and defective Th17 cell differentiation.
© 2009 Taleb et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e2068 SOCS3, IL-17, AND ATHEROSCLEROSIS | Taleb et al.
mice  (Seki  et  al.,  2003).  As  expected,  we  found  reduced   
P­STAT3 in SOCS3­Tg T cells (unpublished data). After   
6 wk of a high fat diet, spleen­derived CD4+ cells of mice 
transferred with CD4+ SOCS3­Tg cells showed reduced pro­
duction of IL­17 and IL­10 but enhanced production of IL­4 
(Fig. S1 e). This is consistent with previous studies that showed 
reduced  Th17  and  preferential  Th2  cell  differentiation  of   
T cells isolated from SOCS3­Tg mice (Seki et al., 2003; 
Tanaka et al., 2008). Interestingly, we found a fourfold in­
crease of lesion size in Apoe//Rag2/ mice transferred with 
CD4+ SOCS3­Tg cells compared with controls (Fig. S1 e), de­
spite similar plasma cholesterol levels (12.1 ± 1.6 vs. 14.1 ± 
0.78 g/liter; P = 0.25). Thus, SOCS3 expression in T cells 
significantly affects atherosclerotic lesion development.
SOCS3 deletion in T cells enhances IL­10  
and IL­17 production
The reduction of atherosclerosis in SOCS3­cKO mice was 
associated with a significant decrease of T cell infiltration 
within the lesions (Fig. 1 b), suggesting a modulation of the 
T cell phenotype. We found no difference in the number and 
suppressive function of natural CD4+CD25+Foxp3+ regula­
tory T cells between the two groups of mice (Fig. S2). Thus, 
we analyzed cytokine production by purified spleen­derived 
CD4+ cells. We observed a significant reduction of IFN­ 
production and an increase of IL­10 by cells recovered from 
SOCS3­cKO mice (Fig. 1 c), which was consistent with pre­
vious results showing preferential Th3­ and/or Tr1­like dif­
ferentiation and reduced Th1 polarization in mice lacking 
SOCS3 expression in T cells (Kinjyo et al., 2006). However, 
we also detected a threefold increase in IL­17 production   
by the purified SOCS3­deficient CD4+ cells compared with 
controls, consistent with the critical role of STAT3 activation 
in Th17 development (Fig. 1 c; Chen et al. 2006; Dong, 
2008).  Flow  cytometry  analysis  on  freshly  isolated  cells 
showed no cells expressing both IL­17 and IL­10, suggesting 
that in vivo, IL­10 and IL­17 are produced by distinct T cells, 
which  is  in  agreement  with  a  recent  study  showing  that 
RORt+ T cells producing both IL­10 and IL­17 could not 
be observed in vivo (Lochner et al., 2008). Consistent with 
enhanced IL­17 production, we found increased IL­6 but re­
duced IL­27 levels in the circulating blood of SOCS3­cKO 
mice (Fig. S2 c). We also found increased production of IL­6 
by  cultured  SOCS3­cKO  splenocytes.  IL­6  neutralization 
did not alter IL­17 production, indicating that the Th17 pro­
file of SOCS3­cKO cells was independent of IL­6 (Fig. S2 d). 
Thus, our results indicate that in the absence of SOCS3 ex­
pression in T cells, there is a preferential switch toward   
increased production of both IL­10 and IL­17, which helps 
explain seemingly divergent previous results on Th3, Tr1, 
and Th17 cells.
SOCS3 deletion in T cells induces an antiinflammatory 
phenotype in macrophages
It was remarkable that the loss of SOCS3 in one cell type has 
produced significant effects on lesion development, where 
Th1  polarization  in  mice  lacking  SOCS3  expression  in   
T cells (Kinjyo et al., 2006). However, others have reported 
a preferential promotion of Th17 in the absence of T cell–
specific SOCS3 expression (Chen et al., 2006), consistent 
with the critical role of STAT3 activation in Th17 devel­
opment (for review see Dong, 2008). Tr1­related responses 
have been associated with the reduction of atherosclerosis 
(Maron et al., 2002; Mallat et al., 2003), whereas recent 
studies have indirectly associated IL­17 production with 
potentially  proatherogenic  responses  (Eid  et  al.,  2009). 
Still, the direct roles of SOCS3 and IL­17 production in 
the modulation of vascular inflammation and atheroscle­
rotic lesion development remain unknown. The involve­
ment  of  SOCS3­  and  IL­17–related  signaling  pathways   
in  various  inflammatory  diseases  (Bettelli  et  al.,  2007;   
Yoshimura et al., 2007) will certainly promote the devel­
opment of therapeutic strategies aiming at the modulation 
of these pathways to limit disease severity and progression. 
Whether  modulation  of  SOCS3  and  IL­17  production 
would similarly alter the inflammatory process related to 
atherosclerosis remains unknown. We have therefore de­
signed a series of experiments to directly assess the roles of 
T cell–specific SOCS3 and (SOCS3­controlled) IL­17 in 
the modulation of vascular inflammation and atheroscle­
rotic lesion development.
RESULTS AND DISCUSSION
SOCS3 expression in T cells significantly affects 
atherosclerotic lesion development
We first examined the effect of SOCS3 deletion in T cells 
on  the  development  of  atherosclerosis.  We  reconstituted 
low­density  lipoprotein  receptor–deficient  (Ldlr/)  mice 
with either a WT bone marrow from SOCS3flox/flox mice 
(the reconstituted mice are designated SOCS3­WT) or a 
bone marrow from mice with T cell–specific deletion in 
SOCS3 (SOCS3flox/flox:Lck­Cre) generated by a condi­
tional gene targeting approach using a Cre­loxP system (des­
ignated SOCS3­cKO; Yasukawa et al., 2003; Kinjyo et al., 
2006). Phosphorylated (P)­STAT3 was readily detectable in 
atherosclerotic lesions, and we found a marked increase in 
P­STAT3 in spleen­derived T cells from SOCS3­cKO mice 
compared with SOCS­WT mice (Fig. S1), indicating an ef­
ficient and functional deletion of SOCS3 in T cells. We 
therefore quantified lesion size after 6 wk on a high fat diet. 
We  found  an  unexpected  50%  reduction  of  aortic  sinus   
lesion size in SOCS3­cKO mice compared with controls 
(Fig. 1 a), despite similar plasma cholesterol levels (18.4 ± 
0.7 vs. 17.6 ± 0.5 g/liter; P = 0.32). We observed a similar 
protection against atherosclerosis at the levels of the aortic 
sinus and the descending thoracic aorta in a separate set of 
old  Ldlr/  mice  reconstituted  with  SOCS3­cKO  bone 
marrow (Fig. S1 d).
We then tested the effect of SOCS3 overexpression in   
T cells on the development of atherosclerosis (Fig. S1 e). We 
reconstituted Apoe//Rag2/ mice with purified CD4+ 
cells recovered from either WT or SOCS3­transgenic (Tg) JEM VOL. 206, September 28, 2009  2069
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were incubated in the presence of SOCS3­cKO CD4+ cells 
compared with SOCS3­WT CD4+ cells (Fig. 1 e). Macro­
phage death within the lesions is highly promoted by proin­
flammatory signals. We found a significant reduction of IL­12 
and an increase in IL­10 production by macrophages after 
coincubation with SOCS3­cKO CD4+ cells compared with 
coincubation with SOCS3­WT CD4+ cells (Fig. 2 a). In ad­
dition, we found a significant reduction in the expression of 
NOS2 and TNF, and an increase of arginase­1 after coincu­
bation of macrophages with SOCS3­cKO T cells compared 
with SOCS3­WT cells, consistent with a limitation of M1 
phenotype and the preservation of an antiinflammatory po­
tential (Fig. 2 a). These effects persisted when T cells and   
macrophages were physically separated using Transwells, 
suggesting the involvement of soluble factors (Fig. 2 a). Neu­
tralization of IL­10 production and, to a lesser extent IL­17, 
prevented some of the antiinflammatory effects (Fig. 2, c and d), 
many other cell types are involved. Thus, we hypothesized 
that the T cell cytokine profile induced by SOCS3 dele­
tion may modulate the inflammatory response of other cell   
types. In this regard, the innate immune system plays a critical   
role in atherogenesis (Hansson and Libby, 2006). Therefore, 
we examined the impact of SOCS3 deletion in T cells on   
macrophage infiltration and activation. The extent of lesion 
macrophage accumulation was not altered in SOCS3­cKO 
compared  with  SOCS3­WT  mice  (35,022  ±  6,308  vs. 
36,635 ± 5,223 µm2; P = 0.84). We hypothesized that this 
could be related to a differential modulation of macrophage 
survival within the lesions. Interestingly, we found a marked 
reduction in the size of the necrotic core in lesions of SOCS3­
cKO mice (Fig. 1 d). This was confirmed by the reduction of 
lesion Tdt­mediated dUTP­biotin nick­end labeling (TUNEL) 
staining (unpublished data) and a protection against macro­
phage apoptosis when bone marrow–derived macrophages 
Figure 1.  SOCS3 deletion in T cells promotes IL­17 and IL­10 production, inhibits macrophage apoptosis, and limits atherosclerotic lesion 
development. (a) Atherosclerotic lesion size in the aortic root of chimeric Ldlr/ SOCS3-WT or SOCS-cKO mice. Data are representative of four indepen-
dent experiments throughout this work. Dashed lines indicate mean values. (b) Lesion T cell infiltration (red staining; mean values ± SEM). Data are repre-
sentative of three experiments. (c) Reduced IFN- but increased IL-10 and IL-17 production in supernatants of CD3-stimulated CD4+ T cells (means ± SEM 
of five mice per group and two experiments; *, P < 0.05). (d) Necrotic core (nc; trichrome staining) size (means ± SEM) in the aortic root. Representative of 
two experiments and 13 mice per group. (e) Macrophage apoptosis (TUNEL staining) after coincubation with CD4+ cells from SOCS3-WT or SOCS-cKO 
mice (means ± SEM). Representative of three experiments (*, P < 0.05). Bars: (a) 250 µm; (b) 30 µm; (d) 60 µm.2070 SOCS3, IL-17, AND ATHEROSCLEROSIS | Taleb et al.
with a study showing that STAT3 activity in tumor cells 
mediates immune evasion through blockade of inflammatory 
signal production by the innate and adaptive immune system 
(Wang et al., 2004). Further studies will be necessary to iden­
tify the soluble factors responsible for the full change in 
macrophage phenotype.
whereas incubation with IL­10 was associated with an anti­
inflammatory phenotype that persisted after supplementation 
with IL­17 (Fig. 2 e). Our results indicate that SOCS3 sig­
naling in T cells not only affects the T cell phenotype but 
also regulates the production of pro­ and antiinflammatory/
atherogenic mediators by macrophages. This is consistent 
Figure 2.  SOCS3 deletion in T cells promotes an antiinflammatory macrophage phenotype. (a) IL-12 and IL-10 production by macrophages after 
coincubation with CD4+ cells from SOCS3-WT or SOCS-cKO mice in the presence or absence of Transwells. Mean values ± SEM of three to four mice per 
group are shown (*, P < 0.05). (b) TNF-, NOS2, and arginase-1 mRNA expression (arbitrary units relative to GAPDH mRNA expression) by macrophages 
after coincubation with CD4+ cells. Mean values ± SEM of three to four mice per group and three independent experiments are shown (*, P < 0.05). (c and d) 
Quantitative analysis (relative to incubation without neutralizing antibodies) of NOS2, arginase-1, and TNF- mRNA expression in macrophages after 
coincubation with CD4+ cells in the presence of either anti–IL-10 (c) or anti–IL-17 (d) neutralizing antibodies. (e) Quantitative analysis (relative to control 
without incubation with recombinant cytokines) of arginase-1 and TNF- mRNA expression in macrophages after incubation with IL-10, IL-17 or IL-10, 
and IL-17. Values in c–e represent mean values ± SEM of three mice per group and three different experiments.JEM VOL. 206, September 28, 2009  2071
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treated with either a mouse monoclonal anti–IL­17A neu­
tralizing  antibody  (Uyttenhove  and  Van  Snick,  2006;   
Uyttenhove et al., 2007) or an isotype­matched control for 
6 wk (see Materials and methods). Interestingly, neutraliza­
tion of IL­17 did not alter lesion size in SOCS3­WT mice, 
which are highly Th1 biased and produce low levels of   
IL­17, but totally abrogated the atheroprotective effect of   
T cell–specific SOCS3 deletion and led to a marked in­
crease of lesion formation (Fig. 3, a and c). Acceleration of 
lesion development was associated with a marked increase 
in vascular inflammation, as revealed by increased vascular 
cell adhesion molecule (VCAM)–1 expression (Fig. 3 f), marked 
T cell infiltration within the lesions and the adventitia of 
Neutralization of IL­17 abrogates atheroprotection  
in mice with T cell–specific SOCS3 deletion and enhances 
vascular inflammation
The reduction of atherosclerosis in SOCS3­cKO mice was 
associated with a reduction in IFN­ and an increase in 
both IL­10 and IL­17. The pro­ and antiatherogenic roles 
of IFN­ and IL­10, respectively, have been extensively 
addressed in previous studies (Tedgui and Mallat, 2006). 
However, the role of IL­17 in atherosclerosis is still un­
explored. Thus, we examined the direct role of IL­17 pro­
duction  in  the  atheroprotective  effect  of  T  cell–specific 
SOCS3 deletion. We generated additional series of chime­
ric Ldlr/ mice that were put on a high fat diet and were 
Figure 3.  SOCS3­controlled IL­17 production protects against vascular inflammation and atherosclerotic lesion development. Representative 
photomicrographs (a and b) and quantitative analysis (c and d) of atherosclerotic lesion size (a and c) and lesion T cell infiltration (b and d) in the aortic 
root of chimeric Ldlr/ SOCS3-WT or SOCS-cKO mice treated either with a neutralizing anti–IL-17A antibody (anti–IL-17) or an isotype-matched control 
(IgG; n = 7–8 mice per group). The anti–IL-17 in vivo experiment was repeated twice. p-values are shown in c and d. Dashed lines indicate mean values.  
(e) Increased IL-4 but reduced IL-10 production in supernatants of CD3-stimulated CD4+ T cells recovered at the time of sacrifice from chimeric Ldlr/ 
mice treated with a neutralizing anti–IL-17A antibody. Means ± SEM of five mice per group performed in triplicates are shown (*, P < 0.05). (f) VCAM-1 
expression in atherosclerotic lesions (n = 6–8 mice per group and two separate experiments; *, P < 0.05). Bars: (a) 250 µm; (b) 100 µm; (f) 130 µm.2072 SOCS3, IL-17, AND ATHEROSCLEROSIS | Taleb et al.
on a C57BL/6 background) and that supplementation of 
SOCS3­WT mice with IL­17 might inhibit lesion devel­
opment. Thus, we fed 17­wk­old female Ldlr/ mice a 
high fat diet and treated them with either rIL­17 or control 
mouse serum albumin. Administration of rIL­17 led to a 
significant elevation of circulating IL­17 levels (Fig. S3 c) 
and to a moderate but significant elevation of IL­6 produc­
tion (27.5 ± 18.7 vs. 1 ± 0.6 pg/ml; P = 0.008) compa­
rable to levels detected in SOCS3­cKO mice, suggesting 
biological effects. We found no change in T cell cytokine 
profile (Fig. S3 d) or splenocyte inflammatory response 
(unpublished data) in mice treated with rIL­17, indicating 
that at this dosage, IL­17 did not promote inflammatory 
cell activation. Interestingly, we found a significant reduc­
tion of atherosclerotic lesion development in mice supple­
mented with rIL­17 (Fig. 4 a). We reproduced the results 
in a different set of younger 12­wk­old female Ldlr/ mice 
(Fig. 4 a). Of note, atheroprotection was associated with a 
marked inhibition of vascular inflammation as revealed by 
a significant inhibition of vascular T cell infiltration (Fig. 4 b) 
and a 60% reduction of endothelial VCAM­1 expression 
(Fig. 4 c). rIL­17 also reduced IL­1–induced endothelial 
VCAM­1 expression in vitro (Fig. 4 d). These results in­
dicate that IL­17 inhibits high fat–induced vascular inflam­
mation and atherosclerotic lesion development.
anti–IL­17–treated SOCS3­cKO mice (Fig. 3, b and d), 
and a switch toward reduced IL­10 and increased IL­4   
production by spleen­derived CD4+ cells (Fig. 3 e) but   
no change in IFN­ (15.4 ± 0.5 vs. 12.7 ± 1.1 ng/ml   
in SOCS3­WT and SOCS3­cKO, respectively). Regulatory 
T cell function was not altered by anti–IL­17 treatment 
(not depicted), and the proatherogenic effect of IL­17 neu­
tralization in SOCS3­cKO mice was not prevented by IL­10 
supplementation (Fig. S3). These results identify an un­
precedented role for SOCS3­controlled IL­17 in the con­
trol of vascular inflammation and T cell accumulation within 
atherosclerotic lesions, which profoundly affects lesion de­
velopment. Our results are in agreement with a study show­
ing that IL­17 neutralization was associated with enhanced 
T cell infiltration in a model of allergic asthma (Schnyder­
Candrian et al., 2006).
In vivo administration of IL­17 to Ldlr/ mice reduces 
endothelial VCAM­1 expression, vascular T cell infiltration, 
and atherosclerotic lesion development
Neutralization of IL­17 accelerated atherosclerosis in SOCS3­
cKO mice but had no effect on lesion development in 
SOCS3­WT mice (Fig. 3). We reasoned that this apparent 
discrepancy  might  be  caused  by  the  low  level  of  IL­17 
production  by  SOCS3­WT  T  cells  (highly  Th1  biased 
Figure 4.  Supplementation with IL­17 reduces vascular inflammation and limits atherosclerotic lesion development. (a) Atherosclerotic lesion size 
in the aortic root of 17-wk-old female chimeric Ldlr / SOCS3-WT mice fed a high fat diet and treated with rIL-17 or control serum albumin for 5 wk. Two 
different experiments are depicted with eight to nine animals in each group. Young animals were 12 wk old. (b) Lesion and adventitial T cell infiltration in  
17-wk-old animals. Similar results were obtained in young animals (not depicted). (c) Endothelial VCAM-1 expression in IL-17–treated 17-wk-old mice. Results 
represent two separate experiments. (d) One representative example out of three different experiments of a Western blot showing reduction of IL-1–induced 
VCAM-1 expression after mouse endothelial cells are incubated with IL-17. Dashed lines indicate mean values. Bars: (a) 250 µm; (b) 50 µm; (c) 25 µm.JEM VOL. 206, September 28, 2009  2073
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the detection of IL­17 in normal mouse aorta by Western 
blotting using a different antibody (unpublished data). These 
results show that C57BL/6 Ldlr/ mice, which are Th1 
biased, produce low levels of IL­17 in T cells and that vas­
cular wall production of IL­17 decreases during the devel­
opment of atherosclerosis, suggesting a relationship between 
SMC differentiation and IL­17 expression.
Finally, we studied human carotid atherosclerotic arteries 
retrieved from patients undergoing carotid endarterectomy. 
Patients characteristics are given in Table S1. P­Stat3 and   
IL­17 expression were readily detectable in CD3+ cells of 
human plaques (Fig. 6), although not all CD3+ cells expressed 
IL­17 or P­Stat3 (Fig. 6). We could also detect P­Stat3 in 
other cell types, as expected (Fig. 6, and not depicted). Inter­
estingly, we also detected IL­17 expression in vascular SMCs, 
and consistent with our data in mice, we found a clear   
Vascular expression of IL­17 and P­Stat3 is associated  
with plaque stability
We then examined IL­17 expression in mouse atheroscle­
rotic arteries (Ldlr/ mice reconstituted with SOCS3­WT 
or  SOCS3­cKO)  using  immunohistochemistry.  As  ex­
pected,  we  were  unable  to  detect  IL­17  expression  in   
T cells of SOCS3­WT mice (not depicted), and only occa­
sional IL­17+ inflammatory cells were detected in lesions of 
SOCS3­cKO mice (Fig. 5, left, a and b), which may be ex­
plained, at least in part, by the low number of activated 
SOCS3­deficient T cells that infiltrated the lesions. Un­
expectedly, we found a marked staining of IL­17 in medial 
smooth muscle cells (SMCs) of plaque­free areas (which 
was confirmed in normal arteries; Fig. 5, left, e), and the 
staining appeared to be rapidly lost in medial SMCs under­
lying early lipid lesions (Fig. 5, left, c and d). We confirmed 
Figure 5.  Expression of IL­17 in atherosclerotic vessels. (left) Mouse atherosclerosis. (a and b) Occasional staining for IL-17 (red, arrows) in inflam-
matory cells within the intima (i) and adventitia (arrows in b) of SOCS3-cKO mice. (c and d) Representative examples of staining for IL-17 (red, arrows) in 
the media (m) of the aortic sinus (c) and the coronary arteries (d) of SOCS3-cKO mice. Note that IL-17 staining in media was detected in plaque-free areas 
(right of the arrowheads) and was lost in areas where plaques have developed (left of the arrowheads). (e–g) Staining for IL-17 (red/brown) in the media 
of the aortic sinus of WT (e and f) or IL-17A–deficient (g) mice. Note that IL-17 staining almost disappeared after adsorption with the IL-17–specific pep-
tide (f) or in vessels of IL-17A–deficient mice (g). Data are representative of at least 10 different mouse arteries. Bars: (a–d) 45 µm; (e–g) 90 µm. (right) 
Human atherosclerosis. (a) IL-17 staining in the media (m) and adventitia (adv) of carotid plaques. (b) The image is from an area underlying an advanced 
plaque. It shows IL-17 staining in adventitial vessels (arrows), but the media has lost its IL-17 staining. (c) The image is from an area underlying an early 
intimal thickening. It shows staining for IL-17 in the adventitial vessels (arrows) and still diffuse moderate IL-17 staining within the media. (d) Another 
example of IL-17 staining (brown) in an advanced carotid plaque. (e) Disappearance of IL-17 staining after adsorption with the IL-17–specific peptide. 
Data are representative of at least 10 different human arteries. Bars: (a) 250 µm; (b and c) 30 µm; (d and e) 45 µm.2074 SOCS3, IL-17, AND ATHEROSCLEROSIS | Taleb et al.
In conclusion, we show that endogenous expression of 
SOCS3 in T cells interrupts a major regulatory pathway in 
atherosclerosis through inhibition of IL­17 production. Inter­
estingly, patients have been identified with defective STAT3 
signaling (Minegishi et al., 2007) and IL­17 production (Ma 
et al., 2008; Milner et al., 2008), and recent observational 
studies have reported the abnormal occurrence of vascular in­
flammation (van der Meer et al., 2006; Ling et al., 2007) in 
this setting despite the absence of classical cardiovascular risk 
factors. Although the reported vascular abnormalities con­
sisted mainly of inflammatory vascular aneurysms, some cases 
decrease in its expression by medial SMCs underlying ad­
vanced lesions (Fig. 5, right). Interestingly, semiquantitative 
assessment of P­Stat3 and IL­17 expression showed increased 
levels of these two markers in plaques with fibrous (stable) 
compared with atheromatous (unstable) phenotype (Fig. 6). 
Consistent with this finding, increased levels of P­Stat3 were 
significantly associated with a low macrophage content, and 
increased levels of IL­17 were associated with a lower mac­
rophage infiltration and a higher SMC content (Fig. 6). No 
relation was found between Stat3 or P­Stat1 levels and plaque 
phenotype (unpublished data).
Figure 6.  Stat3 phosphorylation and IL­17 expression in human carotid atherosclerotic plaques are associated with markers of plaque sta­
bility. (a) Stat3 phosphorylation (P-Stat3) in CD3+ cells of human carotid atherosclerotic plaques (arrows). Arrowheads show a CD3+ cell with no P-Stat3. 
(b) Detection of P-Stat3 in protein extracts from atheromatous (A) or fibrous (F) carotid plaques using Western blotting. Ponceau red is shown for estima-
tion of sample loading. (c) Semiquantitative analysis of P-Stat3 content of carotid plaques and relation to plaque macrophage (M) content, plaque SMC 
content, and plaque phenotype (atheromatous or fibrous). (d) IL-17 expression in CD3+ cells of human carotid atherosclerotic plaques (arrows). Arrow-
heads show two CD3+ cells with no IL-17 expression. (e) Detection of IL-17 in protein extracts from atheromatous (A) or fibrous (F) carotid plaques using 
Western blotting (the same blot shown for P-Stat3 is shown for IL-17). (e) Semiquantitative analysis of the IL-17 content of carotid plaques and the rela-
tion to plaque macrophage content, plaque SMC content, and plaque phenotype (atheromatous or fibrous). Overall, 40 different atherosclerotic plaques 
from 5 separate experiments were studied. Bars: (a) 30 µm; (c) 60 µm. A.U., arbitrary units.JEM VOL. 206, September 28, 2009  2075
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IL­6 for 15 min according to the manufacturer’s protocol (Cell Signaling 
Technology). Labeled cells were then analyzed by flow cytometry on a flow 
cytometer (Epics XL; Beckman Coulter). IL­17 and IL­10 staining was per­
formed using cytokine secretion assay kits (Miltenyi Biotec).
Western blot analysis. CD4+ cells were stimulated with coated anti­CD3 
and anti­CD28 antibodies (2 µg/ml each) for 60 min. Cells were then pro­
cessed for Western blot analyses. Membranes were probed with antibodies 
directed against SOCS3 (clone 1B2; MBL International), P­Stat3 and Stat3 
protein (Cell Signaling Technology). On saphenous vein endothelial cell ex­
tracts, we quantified VCAM­1 expression by using a specific antibody (R&D 
Systems). On human plaque extracts, P­Stat3, Stat3, and P­Stat1 staining was 
performed using specific antibodies purchased from Cell Signaling Technol­
ogy. Human IL­17 was detected using a monoclonal antibody (clone 41802; 
R&D Systems).
T cell–macrophage co-cultures. Macrophages were prepared from 
mouse bone marrow. Differentiated macrophages were then cultured in   
6­well plates either without T cells or with WT or SOCS3­cKO T cells (106 
cells per well) for 24 h in the presence of 1 µg/ml of soluble anti­CD3 anti­
body, after which the T cells were removed and the different cultures were 
washed twice with PBS and the macrophages were stimulated for 24 h with 
1 µg/ml LPS and 100 U/ml IFN­. In some experiments, SOCS3­WT or 
SOCS3­cKO T cells were incubated in the presence of the neutralizing   
antibodies anti–IL­10 (2 µg/ml; R&D Systems) or anti­IL­17 (10 µg/ml;   
Uyttenhove and Van Snick, 2006), or their corresponding isotype­matched 
controls. In other experiments, 10 ng/ml of the recombinant proteins IL­10 
and/or IL­17 (eBioscience) were added on macrophages for 24 h. Quantita­
tive real­time PCR was performed on an ABI PRISM 7700 (Applied Bio­
systems) in triplicates. Cycle threshold for GAPDH (primers: GAPDH­R, 
5­CGTCCCGTAGACAAAATGGTGAA­3;  GAPDH­L,  5­GCCGT­
GAGTGGAGTCATACTGGAACA­3) was used to normalize gene ex­
pression. Primer sequences of M1 macrophage markers (NOS2 and TNF­)   
and M2 marker (arginase­1) are as follows: NOS2­R, 5­CCAAGCCCTCA­
CCTACTTCC­3;  NOS2­L,  5­CTCTGAGGGCTGACACAAGG­3;   
TNF­–R, 5­GTAGCCCACGTCGTAGCAAAC­3; TNF­–L, 5­CTG­
GCACCACTAGTTGGTTGTC­3; Arg­1–R, 5­CTCCAAGCCAAA­
GTCCTTAGAG­3; Arg­1–L, 5­AGGAGCTGTCATTAGGGACATC­3). 
PCR conditions were 10 min at 95°C; 35 cycles of 95°C for 15 s, 60°C for 
20 s, and 72°C for 20 s; and a final extension at 72°C for 20 s. On superna­
tants, ELISAs were performed to measure IL­10 and IL­12 (BD) of the   
different conditions. TUNEL staining was performed on macrophages to 
analyze apoptosis.
Human carotid plaques. The processing and examination of the dissected 
atherosclerotic plaques has been described previously (Ho et al., 1995;   
Verhoeven et al., 2004). All stainings were examined microscopically and 
plaque characteristics were scored semiquantitatively, as described previously 
(Verhoeven et al., 2004). In brief, no or minor (categorized as “low”) mac­
rophage and SMC infiltration represents absent or minimal staining with few 
clustered cells, whereas moderate and heavy represent moderate or heavy 
staining with larger areas of clustered cells (categorized as “high”). The size 
of the lipid core was estimated as a percentage of total plaque area with a di­
vision in three categories: <10% (fibrous plaques), 10–40% (fibroatheromatous 
plaques), and >40% (atheromatous plaques). Recently, we have demonstrated 
that our semiquantitative analysis of atherosclerotic plaque histology is well 
reproducible, both intra­ and interobserver (Hellings et al., 2007). 40 carotid 
atherosclerotic plaques (Table S1) were used for determination of P­Stat3, 
Stat3, P­Stat1, Stat1, and IL­17 expression. Some of these were also used for 
immunohistochemical staining. The plaques were from the Athero­Express 
study, a longitudinal vascular biobank study in which participants provided 
written informed consent, and the study was approved by the Medical 
Ethics Committee of the University Medical Center Utrecht. Other 
plaques used for immunohistochemical staining were previously described 
(Boddaert et al., 2005).
of coronary atherosclerosis have been reported in these young 
individuals (Freeman et al., 2007). Thus, our results may have 
important implications for the understanding of the patho­
physiological mechanisms of vascular inflammation in humans 
and identify novel targets for disease modulation.
MATERIALS AND METHODS
Animals. We subjected 12­ or 24­wk­old C57BL/6 Ldlr/ female mice 
to medullar aplasia by 9.5 Gy of lethal total body irradiation. We repopu­
lated the mice with an intravenous injection of bone marrow cells isolated 
from femurs and tibias of female C57BL/6 SOCS3­WT mice (SOCS­
3flox/flox) or littermate mice with a T cell–specific deletion in SOCS3 
(SOCS3flox/flox:Lck­Cre) generated by a conditional gene targeting ap­
proach using a Cre­loxP system (Yasukawa et al., 2003). The SOCS3fl/ 
fl­Lck­Cre mice were 87.5% C57BL/6 and 12.5% 129 and were inter­
crossed for >10 generations, indicating that they were on a homogeneous 
background. After 4 wk of recovery, mice were fed a high fat diet contain­
ing 15% fat, 1.25% cholesterol, and 0% cholate for 6 wk. In some experi­
ments, the reconstituted mice received an i.p. injection of either purified 
neutralizing anti–IL­17A–specific antibody (200 µg/mouse, twice per week; 
Fig. S4; Uyttenhove and Van Snick, 2006; Uyttenhove et al., 2007) or 
IgG1 control for 6 wk. In others experiments using anti–IL­17A antibody 
or IgG control, we injected i.p. the reconstituted SOCS3flox/flox:Lck­
Cre mice with recombinant mouse IL­10 (eBioscience) diluted in PBS 
0.05% mouse albumin (2 µg/mouse, twice per week) or PBS 0.05% albu­
min for 6 wk. In another set of experiments, we treated i.p. 12­ or 17­wk­
old  C57BL/6  Ldlr/  female  mice  with  recombinant  mouse  IL­17A 
(eBioscience) diluted in PBS 0.05% mouse albumin (2 µg/mouse, twice 
per week) or PBS 0.05% albumin during 5 wk of a high fat diet. Finally, 
6­wk­old male C57BL/6 Apoe//Rag2/ mice (provided by P. Gourdy, 
Institut  National  de  la  Santé  et  de  la  Recherche  Médicale,  Toulouse, 
France) were transferred intravenously with 3 × 106 CD4+ cells recovered 
from either C57BL/6 SOCS3­WT or C57BL/6 SOCS3­overexpressing 
Tg (SOCS3­Tg; Seki et al., 2003), and were put on high fat diet for 6 wk. 
Experiments were conducted according to the French veterinary guide­
lines and those formulated by the European Community for experimental 
animal use (L358­86/609EEC), and were approved by the Institut Na­
tional de la Santé et de la Recherche Médicale.
Extent and composition of atherosclerotic lesions. Quantification of 
lesion size and composition was performed as previously described (Taleb   
et al., 2007). TUNEL staining was performed on fixed cryostat sections as 
previously described (Ait­Oufella et al., 2007). Anti–mouse VCAM­1 anti­
body (clone 429) was obtained from BD. Tyrosine 705 phosphorylation of 
Stat3 was detected in the plaque using rabbit anti–P­Stat3 antibody (Cell 
Signaling Technology). IL­17 staining in the plaque was performed using a 
validated anti–human/mouse IL­17 antibody from Santa Cruz Biotechnol­
ogy, Inc. (Takahashi et al., 2008). The IL­17A–deficient mice were pro­
vided by Y. Iwakura (University of Tokyo, Tokyo, Japan).
Cell recovery and purification, culture, proliferation, and cytokine 
assays. CD11c+, CD4+CD25+, and CD4+CD25– cells were purified and 
processed for cell proliferation assays and cytokine production as previously 
described in detail (Taleb et al., 2007). In some experiments (Fig. S3), 2 × 
105 CD4+ T cells per well were stimulated in anti­CD3–coated (2 µg/ml) 
and anti­CD28–coated (2 µg/ml) microplates for 48 h in the absence of 
CD11c+ cells. IL­4, IL­10, IL­17, and IFN­ productions in the superna­
tants were measured using specific ELISAs (BD and R&D Systems).
Flow cytometry. Splenocytes were labeled with FITC­conjugated anti­
CD4 (clone GK1.5; Miltenyi Biotec), and intracellular Foxp3 staining was 
performed using PE­conjugated anti–mouse/rat Foxp3 (PFJK­16s; eBiosci­
ence) according to the manufacturer’s instructions (eBioscience). Anti–P­
Stat3 staining was performed on CD4+ T cells stimulated with 100 ng/ml 2076 SOCS3, IL-17, AND ATHEROSCLEROSIS | Taleb et al.
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